Rapid Detection of KRAS G12C Mutations with the EntroGen Kit

Discover a Turning Point in Colorectal Cancer Treatment: The KRAS G12C Test Kit and an FDA-Approved Therapy

The FDA has just approved the combination therapy sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with colorectal cancer (CRC) harboring the KRAS G12C mutation. This is an important turning point in oncology:

- A 3-fold increase in progression-free survival (PFS) compared with previous treatments.

- A markedly improved overall response rate (ORR), bringing new hope to millions of patients.

Figure 1: FDA approves the combination of sotorasib and panitumumab for the treatment of patients with colorectal cancer (CRC) harboring the KRAS G12C mutation

The Importance of KRAS G12C Mutation Testing

In cancer treatment, time and accuracy are vital. Early and accurate detection of the KRAS G12C mutation not only helps physicians make appropriate treatment decisions but also directly affects patients' chances of survival and quality of life.

The RAS Mutation Screening Panel Multi-Gene Test Kit from Entrogen (USA) Is an Indispensable Tool

- Accurate detection: Rapid identification of the KRAS G12C mutation along with 34 other mutations in the KRAS and NRAS genes.

- Optimal treatment regimens: Helps physicians select targeted therapies and optimize treatment efficacy.

- Saves precious time: Real-time PCR technology delivers results in just a few hours, shortening waiting times and speeding up treatment.

Figure 2: RAS Mutation Screening Panel kit - Entrogen (USA).

Benefits for Patients

Access to personalized therapy: With the EntroGen kit, each patient is assessed based on their own genetic profile, ensuring they receive the most suitable therapy.

- Increased chances of survival: Targeted treatment based on accurate test results helps patients make the most of the new therapy's efficacy.

- Reduced financial and psychological burden: Accurate detection from the outset helps avoid ineffective therapies, reducing costs and prolonged treatment time.

- Improved long-term health: Detecting and treating the right mutation not only prolongs life but also improves the quality of life of patients and their families.

Let's Bring New Hope to Patients Together!

With the EntroGen kit, physicians can make accurate and effective treatment decisions, helping patients access the most optimal therapy. Correct detection of the KRAS G12C mutation not only prolongs survival but also improves patients' quality of life.

Take action today to give patients a new chance at life and bring this breakthrough therapy into clinical practice. Contact us to join hands in starting a journey that changes patients' lives!

VIET HUY - Connecting Global Technology, Joining Hands for Community Health.